Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation

Bone Marrow Transplant. 1999 Mar;23(6):607-12. doi: 10.1038/sj.bmt.1701627.

Abstract

Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF. Seven patients achieved CR or had normal hemopoietic reconstitution: two had an early relapse at days +53 and +48, two patients died from acute GVHD at days +31 and +96, one died of interstitial pneumonia at day +55, and two patients experienced long-term survival. One patient with refractory disease and nodal involvement who did not respond to the first BMT had overt expansion of the leukemia at day +36; one patient with Ph+ ALL and one with ANLL evolving from MDS, both with skin involvement, had blast cells in peripheral blood at day +27 and +26, respectively. Transient cytopenia occurred in all patients; a normal granulocyte and platelet count was achieved within 3 weeks in all patients but one; acute GVHD occurred in six patients, and four had chronic GVHD. This approach is feasible in patients in early relapse after allo-BMT. It assists prompt re-establishment of normal donor hematopoiesis avoiding the prolonged cytopenia observed after donor lymphocyte infusion in AL patients relapsed after allo-BMT.

MeSH terms

  • Acute Disease
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Transplantation* / immunology
  • Bone Marrow Transplantation* / pathology
  • Combined Modality Therapy
  • Cytarabine / therapeutic use
  • Etoposide / therapeutic use
  • Graft vs Host Disease / chemically induced
  • Graft vs Host Disease / mortality
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cell Mobilization
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia / drug therapy
  • Leukemia / pathology
  • Leukemia / therapy*
  • Mitoxantrone / therapeutic use
  • Recurrence
  • Time Factors
  • Tissue Donors
  • Transplantation Chimera
  • Transplantation, Homologous

Substances

  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Mitoxantrone

Supplementary concepts

  • MAV protocol